375 related articles for article (PubMed ID: 16399595)
1. Graft-versus-host disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresis.
Komanduri KV; Couriel D; Champlin RE
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):1-6. PubMed ID: 16399595
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Prevention and treatment of acute GvHD.
Messina C; Faraci M; de Fazio V; Dini G; Calò MP; Calore E;
Bone Marrow Transplant; 2008 Jun; 41 Suppl 2():S65-70. PubMed ID: 18545247
[TBL] [Abstract][Full Text] [Related]
4. Extracorporeal photopheresis in chronic graft-versus-host disease.
Foss FM; Gorgun G; Miller KB
Bone Marrow Transplant; 2002 May; 29(9):719-25. PubMed ID: 12040467
[TBL] [Abstract][Full Text] [Related]
5. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?
Couriel D; Hosing C; Saliba R; Shpall EJ; Andelini P; Popat U; Donato M; Champlin R
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):37-40. PubMed ID: 16399600
[TBL] [Abstract][Full Text] [Related]
6. The role of the extracorporeal photopheresis in the management of the graft-versus-host disease.
Kaloyannidis P; Mallouri D
Transfus Apher Sci; 2012 Apr; 46(2):211-9. PubMed ID: 22123355
[TBL] [Abstract][Full Text] [Related]
7. Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression?
Marshall SR
Nat Clin Pract Oncol; 2006 Jun; 3(6):302-14. PubMed ID: 16757968
[TBL] [Abstract][Full Text] [Related]
8. Care for patients undergoing extracorporeal photopheresis to treat chronic graft-versus-host disease: review of the evidence.
Woltz P; Castro K; Park BJ
Clin J Oncol Nurs; 2006 Dec; 10(6):795-802. PubMed ID: 17193945
[TBL] [Abstract][Full Text] [Related]
9. Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
Hess AD
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):13-21. PubMed ID: 16399597
[TBL] [Abstract][Full Text] [Related]
10. The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation.
Schneider M; Munder M; Karakhanova S; Ho AD; Goerner M
Clin Lab Haematol; 2006 Dec; 28(6):382-90. PubMed ID: 17105491
[TBL] [Abstract][Full Text] [Related]
11. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature.
Kanold J; Merlin E; Halle P; Paillard C; Marabelle A; Rapatel C; Evrard B; Berger C; Stephan JL; Galambrun C; Piguet C; D'Incan M; Bordigoni P; Deméocq F
Transfusion; 2007 Dec; 47(12):2276-89. PubMed ID: 17764513
[TBL] [Abstract][Full Text] [Related]
12. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
13. The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
Sánchez-García J; Serrano J; Gómez P; Martínez F; Martín C; Román-Gómez J; Rodríguez A; Herrera C; García JM; Alvarez MA; Torres A
Haematologica; 2006 Mar; 91(3):340-7. PubMed ID: 16531257
[TBL] [Abstract][Full Text] [Related]
14. Chronic graft-versus-host disease: clinical manifestation and therapy.
Ratanatharathorn V; Ayash L; Lazarus HM; Fu J; Uberti JP
Bone Marrow Transplant; 2001 Jul; 28(2):121-9. PubMed ID: 11509929
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation.
Dander E; Balduzzi A; Zappa G; Lucchini G; Perseghin P; Andrè V; Todisco E; Rahal D; Migliavacca M; Longoni D; Solinas G; Villa A; Berti E; Mina PD; Parma M; Allavena P; Biagi E; Rovelli A; Biondi A; D'Amico G
Transplantation; 2009 Dec; 88(11):1261-72. PubMed ID: 19996925
[TBL] [Abstract][Full Text] [Related]
16. Graft-versus-host disease in allogeneic bone marrow transplantation: the role of monoclonal antibodies in prevention and treatment.
Hiscott A; McLellan DS
Br J Biomed Sci; 2000; 57(2):163-9. PubMed ID: 10912294
[TBL] [Abstract][Full Text] [Related]
17. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?
Har-Noy M; Slavin S
Med Hypotheses; 2008; 70(6):1186-92. PubMed ID: 18054441
[TBL] [Abstract][Full Text] [Related]
18. Recent compounds for immunosuppression and experimental therapies for acute graft-versus-host disease.
Michael M; Shimoni A; Nagler A
Isr Med Assoc J; 2013 Jan; 15(1):44-50. PubMed ID: 23484241
[TBL] [Abstract][Full Text] [Related]
19. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease.
Biagi E; Di Biaso I; Leoni V; Gaipa G; Rossi V; Bugarin C; Renoldi G; Parma M; Balduzzi A; Perseghin P; Biondi A
Transplantation; 2007 Jul; 84(1):31-9. PubMed ID: 17627234
[TBL] [Abstract][Full Text] [Related]
20. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
